Grace Therapeutics, Inc. (GRCE): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$8.87M

Year ended 2026-03-31

-$10.29M

Trailing 12 months to 2026-06-30

2020-03-31 Operating Cash Flow (USD) 2026-03-31

Period ended	Operating Cash Flow	Change YoY	Source filing
2026-03-31	-$8.87M	n/m	2026-06-18, From 2025-04-01
2025-03-31	-$14.90M	n/m	2026-06-18, From 2024-04-01
2024-03-31	-$12.33M	n/m	2025-06-23, From 2023-04-01
2023-03-31	-$15.91M	n/m	2024-06-21, From 2022-04-01
2022-03-31	-$17.23M	n/m	2023-06-23, From 2021-04-01
2021-03-31	-$14.32M	n/m	2022-06-21, From 2020-04-01
2020-03-31	-$22.95M	n/a	2021-06-22, From 2019-04-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
Grace Therapeutics, Inc. (GRCE)	2026-03-31	-$8.87M	n/m
Context Therapeutics Inc. (CNTX)	2025-12-31	-$26.39M	n/m
Spero Therapeutics, Inc. (SPRO)	2025-12-31	-$12.62M	n/m
Werewolf Therapeutics, Inc. (HOWL)	2025-12-31	-$60.29M	n/m
Corvus Pharmaceuticals, Inc. (CRVS)	2025-12-31	-$32.80M	n/m
Rallybio Corp (RLYB)	2025-12-31	-$29.81M	n/m
OnKure Therapeutics, Inc. (OKUR)	2025-12-31	-$51.83M	n/m
Lifevantage Corp (LFVN)	2026-06-30	$10.24M	-13.8%
AN2 Therapeutics, Inc. (ANTX)	2025-12-31	-$29.83M	n/m

Compare GRCE, CNTX, SPRO, HOWL side by side · Screen every company in Pharmaceutical Preparations ↗